|
| |
BioPortfolio's Approved Drugs DatabaseDacogenDecitabineDownload PDF containing detailed information.
Press Releases About Dacogen:
|
 |
| Updated NCCN Guidelines for AML Include Risk Stratification to Assist in Treatment Selection |
19th October, 2009 |
National Comprehensive Cancer Network |
The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Guidelines for Acute Myeloid Leukemia (AML), the most common acute leukemia affecting adults. Noteworthy updates include the
|
| FDA Accepts sNDA for Alternative Dosing Regimen for Dacogen(R) (decitabine for injection) to Treat Patients with Myelodysplastic Syndromes (MDS) |
8th July, 2009 |
Eisai Corporation of North America |
WOODCLIFF LAKE, N.J., July 8 /PRNewswire/ -- Eisai Corporation of North America today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's supplemental
|
| Celgene's Vidaza and Revlimid Will Capture 70 Percent of the Myelodysplastic Syndromes Drug Market |
5th May, 2009 |
Decision Resources |
The Need for More-Efficacious Treatments Creates Significant Opportunity for Drug Developers in this Niche Market, According to a New Report from Decision Resources
WALTHAM, Mass., May 5 /PRNewswire/
|
| Dacogen(R) (decitabine for injection) Data Presented on a Phase II Clinical Trial in Elderly Patients with Acute Myeloid Leukemia (AML) |
8th December, 2008 |
Eisai Inc. |
Response Observed Across All Subtypes of AML, Including Those with Poorest Prognoses
SAN FRANCISCO, Dec. 8 /PRNewswire/ -- Eisai Corporation of North America today announced data from a Phase II
|
| SuperGen Reports 2008 Third Quarter Financial Results |
4th November, 2008 |
SuperGen, Inc. |
DUBLIN, Calif., Nov. 4 /PRNewswire-FirstCall/ -- SuperGen, Inc.
(Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery and
development of novel cancer therapies, today announced
|
Companies working in the area of Dacogen from Bioportfolio's Biocorporate database : | |
| Company Name | |
DACOGEN is indicated for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British (FAB) subtypes ...
www.dacogen.com/ View full profile
| |
This page has been viewed 26 times
Recent Search Terms used to find this page: Dacogen logo | .
Browse BioPortfolio's InDepth service - alphabetically:
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
or by Most Publications, recently searched for, or
most viewed.
Search for Dacogen across BioPortfolio, or for Dacogen Research Reports
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH.
Thumbshots from Thumbshots.org
|
